 NEW YORK--BUSINESS WIRE--- RCKT GeneTherapy--Rocket Pharmaceuticals, Inc. NASDAQ: RCKT Rocket, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial results for the quarter that ended September 30, 2020, along with an update on the Companys key pipeline developments, business operations and upcoming milestones. We are incredibly pleased with the steady progress we made across all five of our clinical programs t 